Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 10/20 | 0.49 |
| ▸ | RAB9A | P51151 | 10/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.49 |
| ▸ | MEN1 | O00255 | 8/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852596 | 1.00 | USP30 (0.52) | USP30MAPTNPC1RAB9AKMT2A | |
| SCHEMBL22341606 | 0.79 | NPC1 (0.58) | USP30MAPTNPC1RAB9AKMT2A | |
| SCHEMBL8863163 | 0.78 | LDHA (0.57) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL25854530 | 0.78 | NPC1 (0.55) | USP30MAPTNPC1RAB9AKMT2A | |
| SCHEMBL13675829 | 0.75 | MEN1 (0.58) | USP30NPC1RAB9AKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL5548005 | 0.74 | NPC1 (0.57) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL411193 | 0.74 | RAB9A (0.57) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL14697393 | 0.74 | NPC1 (0.54) | NPC1RAB9AKMT2AMEN1GFER | |
| SCHEMBL12354787 | 0.74 | NTRK1 (0.55) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL8757250 | 0.74 | NPC1 (0.57) | USP30NPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338966-B2 | Substituted oxindole derivatives as tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7129253-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-7071217-B2 | Substituted oxindole derivatives as tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050228025-A1 | Substituted oxindole derivatives as tyrosine kinase inhibitors | DICKERSON SCOTT H | 2005-10-13 | — | — | US | disclosed |
| US-6818632-B2 | 3-(anilinomethylene)oxindoles | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| US-20040191210-A1 | Compounds | GLENNON KIMBERLEY CAROLINE (US) | 2004-09-30 | — | — | US | disclosed |
| EP-1009738-B1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-20030195234-A1 | Substituted oxindole derivatives as tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-10-16 | — | — | US | disclosed |
| EP-1339680-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-09-03 | — | — | EP | disclosed |
| US-6498176-B1 | INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS | SMITHKLINEBEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | GLENNON KIMBERLEY CAROLINE (US) | 2002-07-25 | — | — | US | disclosed |
| US-6387919-B1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | GLAXO WELLCOME INC. | 2002-05-14 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| WO-2002020479-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-03-14 | — | — | WO | disclosed |
| US-6350747-B1 | PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | GLAXO WELLCOME INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
| EP-1009738-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999015500-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040191210-A1 | Compounds | CDK1, AKT1, RPS6KA1 | USP30 3777/4885MAPT 2084/4885NPC1 3881/4885 |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | PRKDC, PRKX, BMX | USP30 3273/4885MAPT 2317/4885NPC1 4728/4885 |
| US-20030195234-A1 | Substituted oxindole derivatives as tyrosine kinase inhibitors | FRK, LTK, ERBB2 | USP30 3638/4885MAPT 1604/4885NPC1 4260/4885 |
| US-20050228025-A1 | Substituted oxindole derivatives as tyrosine kinase inhibitors | LTK, FRK, ERBB2 | USP30 4168/4885MAPT 3043/4885NPC1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.